Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Environ Mol Mutagen. 2010 Jun;51(5):462-75. doi: 10.1002/em.20554.
Mitochondria are key organelles that perform essential cellular functions and play pivotal roles in cell death and survival signaling. Hence, they represent an attractive target for drugs to treat metabolic, degenerative, and hyperproliferative diseases. Targeting mitochondria with organelle-specific agents or prodrugs has proven to be an effective therapeutic strategy. More specifically, controlling the cellular ROS balance via selective delivery of an antioxidant "payload" into mitochondria is an elegant emerging therapeutic concept. Herein, we review the recent medicinal chemistry and clinical data of these exploratory strategies, which should point the way for future generations of therapeutics.
线粒体是执行重要细胞功能并在细胞死亡和存活信号中发挥关键作用的关键细胞器。因此，它们代表了治疗代谢、退行性和过度增殖性疾病的药物的有吸引力的靶点。使用细胞器特异性试剂或前药靶向线粒体已被证明是一种有效的治疗策略。更具体地说，通过选择性地将抗氧化剂“有效载荷”递送到线粒体中来控制细胞内 ROS 平衡是一种优雅的新兴治疗概念。本文综述了这些探索性策略的最新药物化学和临床数据，这些数据应该为下一代治疗药物指明方向。
